Last updated: March 12, 2026
What are the primary sources for bulk clascoterone API?
Clascoterone is a topical androgen receptor inhibitor developed for acne and androgen-related skin conditions. It is not yet widely available commercially in large-scale APIs. Its production relies on specialized chemical synthesis routes, and only select pharmaceutical ingredient (API) manufacturers globally produce or supply it at scale.
Who are the main API manufacturers for clascoterone?
Currently, no publicly available, large-scale, commercial API manufacturers produce clascoterone in significant quantities. The API was developed primarily by Cassiopea SpA, which filed for U.S. FDA approval in 2020 for epidermal applications. Clinical trial phases were conducted with proprietary manufacturing processes, suggesting limited supplier diversity at this stage.
Potential API suppliers based on industry practices
Since clascoterone is a novel molecule patented by Cassiopea, existing APIs are not supplied via open market channels. Instead, API manufacturing is likely conducted under exclusive agreements with contract manufacturing organizations (CMOs). These CMOs may include companies with the capacity for complex steroidal synthesis, such as:
- Lonza: Known for custom steroid API manufacturing, with capabilities in complex synthetic routes.
- BASF: Supplies API synthesis services, including steroid-based compounds.
- Recipharm: Offers custom synthesis for niche APIs and advanced pharmaceuticals.
- Samsung Biologics: While primarily focused on biologics, it has expanded into small-molecule API contract manufacturing.
Because of the proprietary nature of the process and patent protections, the actual API source is limited to Cassiopea's licensed or partnered CMOs.
Manufacturing process considerations
Clascoterone synthesis involves complex steroidal chemical steps, including:
- Multiple stereoselective reactions to produce the androgen receptor antagonist structure.
- Specific protecting group strategies to ensure regioselectivity.
- Purification steps to meet pharmaceutical quality standards (e.g., USP, EP).
These steps typically require specialized facilities capable of handling steroidal intermediates efficiently and safely.
Regulatory factors influencing API sourcing
The API must meet stringent quality standards imposed by regulatory agencies like the FDA and EMA. This restricts sources to approved, cGMP-compliant manufacturers. The limited number of qualified facilities restricts API supply options in the early commercialization phase.
Summary
- No publicly available bulk API sources for clascoterone exist currently at commercial scale.
- Manufacturing is likely limited to Cassiopea's licensed CMOs, emphasizing proprietary, high-quality production.
- Lead suppliers include companies with expertise in steroid synthesis, such as Lonza, BASF, Recipharm, and possibly Samsung Biologics.
- The proprietary synthesis route and patent protections constrain the emergence of multiple suppliers.
Key Takeaways
- Clascoterone API production is tightly controlled and proprietary.
- Major API suppliers are likely CMOs specializing in complex steroid synthesis.
- Limited supplier diversity exists at present due to patent rights and manufacturing complexity.
- Regulatory compliance restricts API sourcing to qualified manufacturing facilities.
- Future API availability depends on commercial scale-up and licensing agreements.
FAQs
1. Are there any approved bulk API suppliers for clascoterone?
No. As of now, no third-party suppliers publicly offer bulk API for clascoterone; manufacturing is confined to Cassiopea’s licensed facilities or their contract manufacturers.
2. Which companies have the capacity to produce steroidal APIs like clascoterone?
Companies such as Lonza, BASF, and Recipharm possess the capacity to manufacture complex steroidal APIs and have experience in high-quality, cGMP production.
3. How does patent protection affect API sourcing for clascoterone?
Patent protections restrict manufacturing rights and sourcing options, limiting production to authorized manufacturers under licensing agreements.
4. When might bulk API for clascoterone become more widely available?
Until commercial approval and licensing agreements expand, API availability remains limited. Larger-scale manufacturing may occur upon commercialization, possibly within the next 1-3 years.
5. What are the main challenges in manufacturing API for clascoterone?
The main challenges include complex stereoselective synthesis, maintaining manufacturing quality, and ensuring regulatory compliance specific to steroidal APIs.
References
[1] Cassiopea SpA. (2020). Press Release: Clinical trial updates for acne treatment.
[2] FDA. (2021). Guidance for Industry: Quality Considerations for API Manufacturing.
[3] Lonza. (2022). Custom Manufacturing Capabilities.
[4] BASF. (2021). Pharmaceutical Ingredient Synthesis.
[5] Recipharm. (2020). Steroid API Production Services.
